ArticleWorld journal of surgical oncology2026
CCL chemokines as prognostic and immunotherapeutic markers in prostate cancer: a comprehensive analysis.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum CCL2 and CCL7 in Prostate Cancer: Evaluation of Their Diagnostic Utility in Comparison with Benign Prostatic Hyperplasia and Healthy Controls.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to delineate the prognostic significance of CCL family expression in Prostate Cancer (PCa) and explore their immunomodulatory roles to assess therapeutic potential.
methodsWe identified CCL family expression profile utilizing ONCOMINE, and their relationship with the pathological stage and Gleason Score of PCa patients. The genetic alterations and protein-protein interactions were investigated in PCa. Subsequently, Transcriptional regulatory networks were established using TRRUST database. The immunocyte infiltration expression profile was investigated based on the CCL expression. Go and KEGG analysis was employed to further explore the biological functions and pathways. Finally, we verified the CCL gene expression using in vitro PCR experiments.
resultsThe findings revealed a notable elevation in the expression levels of CCL11/14/16/18/19 in PCa, whereas the expression of CCL2/7/8/17/23/25 were significantly decreased in PCa compared to the expression levels in normal tissues.High expression of both CCL3 and CCL4 was significantly associated with shorter disease-free survival.CCL8/22/24 and CCL3/11/17/18/19/22 was associated with high pathological N stage and high Gleason Score, respectively. High expression of CCL11/17/18/22/24 and CCL3/11/17/18/19/22 was associated with high pathological N stage and high Gleason Score, respectively.
conclusionsThe findings may provide insights and evidence on the potential application of CCL chemokines as immunotherapeutic treatment targets and prognostic biomarkers for PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.